ICIs, either single-agent anti-programmed cell death protein-1 (PD-1) or in combination with anti-CTLA-4 (refs. 1,2) or other immune checkpoints3, are approved first-line therapies for MM. This evidence concerns the gene CTLA4 and Miyoshi myopathy.